Active, not recruitingNot applicableNCT03115333
DSC-MRI in Measuring rCBV for Early Response to Bevacizumab in Patients With Recurrent Glioblastoma
Studying Gliosarcoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- ECOG-ACRIN Cancer Research Group
- Principal Investigator
- Jerrold Boxerman, MDECOG-ACRIN Cancer Research Group
- Intervention
- Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging(diagnostic_test)
- Enrollment
- 146 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2017 – 2027
Study locations (30)
- Saint Joseph's Hospital and Medical Center, Phoenix, Arizona, United States
- Mayo Clinic Hospital, Phoenix, Arizona, United States
- Mayo Clinic in Arizona, Scottsdale, Arizona, United States
- Eden Hospital Medical Center, Castro Valley, California, United States
- Loma Linda University Medical Center, Loma Linda, California, United States
- USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
- UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California, United States
- VA Palo Alto Health Care System, Palo Alto, California, United States
- Boca Raton Regional Hospital, Boca Raton, Florida, United States
- Baptist MD Anderson Cancer Center, Jacksonville, Florida, United States
- Mayo Clinic in Florida, Jacksonville, Florida, United States
- Moffitt Cancer Center-International Plaza, Tampa, Florida, United States
- Moffitt Cancer Center - McKinley Campus, Tampa, Florida, United States
- Moffitt Cancer Center, Tampa, Florida, United States
- Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03115333 on ClinicalTrials.govOther trials for Gliosarcoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07134842A Study Assessing if it is Safe and Possible to Treat Brain Cancer Patients With Immunotherapy Before They Receive the Standard Treatment.University College, London
- ENROLLING BY INVITATIONPHASE1NCT06896110Intrathecal Azacitidine and Nivolumab in Patients With Recurrent High-grade GliomaAndrew P. Groves
- RECRUITINGPHASE1NCT06934889Study of ABBV-637 or ABBV-155 With ERAS-801 for People With GlioblastomaMemorial Sloan Kettering Cancer Center
- RECRUITINGNCT05756985Improving Understanding of Glioblastoma Through Preservation of Biologically Active Brain TissueBaptist Health South Florida
- RECRUITINGPHASE2NCT05864534Phase 2a Immune Modulation With Ultrasound for Newly Diagnosed GlioblastomaNorthwestern University
- RECRUITINGNCT06954636Prognostic Potential of Olfactory Function in Glioblastoma: a Prospective Observational StudySied Kebir
- RECRUITINGPHASE1NCT04991870Phase I CB-NK-TGF-ßR2-/NR3C1- in rGBMM.D. Anderson Cancer Center
- RECRUITINGPHASE1NCT05363826Intracavitary Photodynamic Therapy as an Adjuvant to Resection of Glioblastoma or Gliosarcoma Using IV Photobac®Photolitec LLC